Perioperative chemotherapy with a docetaxel-based triplet should be considered the new standard of care for resectable gastric or GEJ adenocarcinoma.
Mark L. Fuerst
The second-generation ALK-inhibitor alectinib should be the new standard of care for first-line treatment of ALK-positive non–small-cell lung cancer, according to a new study.
Immunotherapy may represent an effective new treatment approach for relapsed mesothelioma patients, according to a new study.
Breast cancer survivors, including those with estrogen receptor–positive tumors, can safely become pregnant, according to a new study.
Women infected with the human immunodeficiency virus (HIV) are more likely to have human papillomavirus (HPV) infection that progresses to pre-cancerous cervical lesions.
Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non–small-cell lung cancer.
Cytomegalovirus targeted vaccination plus high-dose chemotherapy with temozolomide can lead to long-term progression-free and overall survival in patients with newly diagnosed glioblastoma.
A nivolumab/ipilimumab combination significantly improved overall survival for advanced melanoma patients.
Young men who are overweight or obese are at risk of developing severe liver disease or liver cancer in later life, particularly those who have type 2 diabetes mellitus.
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices.